Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ANPEP | P15144 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ICMT | O60725 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28690894 | 0.83 | BCL2L1 (0.56) | ANPEPRAB9AL3MBTL1NPSR1MMP13 | |
| SCHEMBL28690896 | 0.83 | BCL2L1 (0.56) | ANPEPRAB9AL3MBTL1NPSR1MMP13 | |
| SCHEMBL1997609 | 0.79 | MEN1 (0.69) | KMT2AANPEPL3MBTL1MEN1ALDH1A1 | |
| SCHEMBL1995534 | 0.79 | MEN1 (0.69) | KMT2AANPEPL3MBTL1MEN1ALDH1A1 | |
| SCHEMBL202593 | 0.78 | ANPEP (0.57) | KMT2AANPEPSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL2327144 | 0.77 | KMT2A (0.66) | KMT2ARAB9AL3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL2327147 | 0.77 | KMT2A (0.66) | KMT2ARAB9AL3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL2328766 | 0.76 | FNTA (0.55) | KMT2ARAB9AMEN1ALDH1A1NPSR1 | |
| SCHEMBL2328761 | 0.76 | FNTA (0.55) | KMT2ARAB9AMEN1ALDH1A1NPSR1 | |
| SCHEMBL2324006 | 0.75 | RAB9A (0.53) | KMT2ARAB9AL3MBTL1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2338878-A2 | N-hydroxyamide derivatives possessing antibacterial activity | Vicuron Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | KMT2A 1049/4885ANPEP 418/4885RAB9A 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.